In 2023, Christopher Boerner earned $1.81M in total compensation at Bristol-Myers Squibb, primarily from $1.50M salary. Most recently acquired 2,000 shares in Feb 2025. Currently holds stock worth $293.36K. 2+ years at the helm of Bristol-Myers Squibb.
Compensation History
Annual executive compensation data for Christopher Boerner, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.81M
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Salary
$1.50MBoard Justification
The compensation philosophy emphasizes performance-based pay that aligns with company performance and shareholder interests, with a significant portion of compensation tied to long-term equity incentives.
Bonus
$0.00Board Justification
The annual target bonus opportunity for Christopher Boerner is set at 150% of his base salary, reflecting his performance as CEO starting November 1, 2023.
Other Compensation
$311.64KBoard Justification
Other compensation includes financial planning services, executive physicals, and contributions to savings plans.
Restricted Stock
Board Justification
No stock awards vested in 2023 as the focus was on performance-based equity awards that will vest in future periods.
Performance Metrics
The performance metrics for the annual incentive plan include Non-GAAP diluted EPS, In-Line and New Product Revenue, New Product Portfolio Revenue, Pipeline performance, and ESG scorecard metrics.
Christopher Boerner
CEO of Bristol-Myers Squibb
Education
Ph.D. in Economics from Duke University
Field of Expertise
Other - Economics
Sector of Economy
Healthcare
Born
March 15, 1971 - 54 years ago
CEO of Bristol-Myers Squibb for
2 years 1 month (Nov 2023 - Present)
Previous Experience
Various senior roles within Bristol-Myers Squibb
Other Bristol-Myers Squibb CEOs
Holdings
Track Christopher Boerner's stock holdings and portfolio value over time.
Total Stock Sold
$2.04M
$2.04M
29,532 BMY shares
What if they kept their stock?
If Christopher Boerner didn't sell their stock, today they would have:
Extra BMY29,532 shares worth $1.53M.
This is -24.97% and $510.61K less than what they got when they sold the stock.
Insider Trading
Christopher Boerner's recent stock transactions, purchases, and sales filed with the SEC.
$110.10K
BMY at $55.05/share
Feb 20, 2025
Purchase
$99.56K
BMY at $49.78/share
Dec 5, 2023
Purchase
$150.05K
BMY at $48.86/share
Nov 28, 2023
Purchase
$2.04M
BMY at $69.20/share
Mar 14, 2022
Sale
13,417 shares
BMY
Mar 10, 2022
Received
Rivals
Compare Christopher Boerner with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M